Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode Genenta Science’s gene-therapy disclosures? Clinical-stage biotech filings are packed with trial endpoints, interferon safety data, and cash-runway notes that can stretch far beyond 200 pages. For investors following Temferon’s progress against glioblastoma, missing a single line in a 20-F or 10-Q could mean overlooking critical risk factors or dilution signals.
Stock Titan solves this problem in two clicks. Our AI-powered summaries break down every Genenta Science SEC filings explained simply—from the annual report 10-K simplified to each Genenta Science quarterly earnings report 10-Q filing. Need Form 4 alerts? We push Genenta Science Form 4 insider transactions real-time the moment executives trade shares, so you can track executive stock transactions Form 4 without trolling EDGAR. Material event on pipeline data? A concise brief appears seconds after the Genenta Science 8-K material events explained hits the wire.
Dive deeper when you’re ready. Compare R&D expense trends, analyze licensing revenue with our earnings report filing analysis, or zoom into trial milestones flagged inside 6-K updates. Our platform links filing sections to plain-English notes—highlighting where interferon toxicity is addressed, how FDA feedback reshapes timelines, and why specific warrants convert. Whether you’re asking “How do I read Genenta Science’s proxy statement executive compensation?” or “What did the latest Genenta Science insider trading Form 4 transactions show?”, you’ll find every answer, timestamped and searchable. Understanding Genenta Science SEC documents with AI means spending minutes, not nights, on due diligence.
Genenta Science S.p.A. (GNTA) reported outcomes from its Ordinary and Extraordinary Shareholders’ Meeting. Directors Armon R. Sharei, Francesco Galimi, and CEO Pierluigi Paracchi will continue on the Board, and two new directors were appointed: Miguel Maria Mutti, a senior pharma and investment banking executive, and Giacomoantonio Paracchi, a business lawyer and brother of the CEO.
Shareholders approved an amendment to Article 4 of the by-laws to extend the corporate purpose to sectors covered by Italy’s Golden Power legislation. Effectiveness is expressly conditioned on no shareholder exercising the statutory withdrawal right; a single valid withdrawal makes the amendment ineffective and does not trigger share liquidation. The withdrawal right must be exercised by registered letter within 15 days of registration of the resolution, i.e., by about November 15, 2025.
The amended by-laws were filed as Exhibit 3.1. The filing notes a recent capital increase with 4,285,715 new shares and that updated by-laws reflecting share capital will be filed within 30 days from execution.
Genenta Science S.p.A. (GNTA) is conducting a registered direct primary offering of 4,285,715 ADSs at $3.50 per ADS, for gross proceeds of $15,000,002.50. After placement agent fees of $900,000.15 and estimated expenses, the company expects net proceeds of approximately $13.8 million, which it intends to use for working capital and general corporate purposes. The ADSs are listed on Nasdaq under “GNTA,” and delivery is expected on or about October 28, 2025.
Maxim Group LLC and Rodman & Renshaw LLC are acting as placement agents on a reasonable best efforts basis. The company reports as adjusted net tangible book value of $1.16 per ADS, implying immediate dilution of $2.34 per ADS to new investors. Ordinary Shares outstanding are expected to be 23,432,183 after the offering. The last reported GNTA price on October 24, 2025 was $6.20 per ADS.
Genenta Science S.p.A. (GNTA) entered into a registered direct offering of 4,285,715 ADSs at $3.50 per ADS, for gross proceeds of approximately $15.0 million, expected to close on or about October 28, 2025 subject to customary conditions. Each ADS represents one ordinary share.
The company plans to use net proceeds for working capital and general corporate purposes. The sale is being made under a prospectus supplement to Genenta’s effective Form F-3 shelf.
Maxim Group LLC (lead) and Rodman & Renshaw LLC (co-placement agent) are acting as placement agents; Genenta will pay a 6.0% cash fee on aggregate gross proceeds and up to $75,000 for expenses. For 90 days after closing, the company, and separately its officers and directors under lock-up agreements, agree to restrictions on issuing or selling company securities, with limited exceptions. The company also agreed not to conduct variable rate transactions for six months.
Genenta Science S.p.A. (GNTA) reported outcomes from its April 29, 2025 Annual Ordinary Shareholders’ Meeting. Shareholders approved the statutory financial statements for the year ended December 31, 2024, audited by Revicom.
They appointed three directors effective April 29, 2025, adding Dr. Francesco Galimi as a new member. Armon R. Sharei, Ph.D. continued on the Board, and Pierluigi Paracchi continued as Chairman. The term of office for each newly appointed director is one year.
The aggregate annual directors’ compensation was set at €105,000. On April 30, 2025, the directors appointed Mr. Paracchi as Chief Executive Officer and allocated annual compensation of €45,000 for the CEO and €30,000 for each of Dr. Galimi and Dr. Sharei.
FAQ
What is the current stock price of Genenta Science Spa (GNTA)?
What is the market cap of Genenta Science Spa (GNTA)?
